Skip to main content

HealthCap — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

37
Companies
$1.6B
Total invested
$47.1M
Avg. check
25
Industries
Biotechnology 17Health Care 15Medical 10Therapeutics 10Pharmaceutical 9Life Science 3+19 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 37
Carisma Therapeutics
September 2022

Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.

Biotechnology · Philadelphia$30.0M Series C
CurifyLabs
July 2026

CurifyLabs is a healthtech company focused on the automated compounding of personalized medicines in pharmacies and hospitals.

Health Care · Helsinki$13.7M Series A
Pretzel Therapeutics
July 2025

Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

Biotechnology · WalthamVenture - Series Unknown
Oncorena
June 2025

Oncorena treatment for renal cancer

Biotechnology · Lund$14.0M Venture - Series Unknown
Modus Therapeutics
June 2025

Modus Therapeutics is a Swedish drug development company focused on normalizing the lives for patients with Sickle Cell Disease.

Biotechnology · Stockholm$3.0M Post-IPO Equity
Priothera
June 2025

Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.

Biotechnology · Dublin$2.0M Grant
Spruce Biosciences
April 2026

Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.

Biopharma · South San Francisco$60.0M Post-IPO Equity
Ariceum Therapeutics
April 2023

Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.

Biotechnology · Berlin$25.0M Series A
Precirix
March 2022

Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.

Biotechnology · Brussels$88.2M Series B
Vivet Therapeutics
February 2024

Vivet Therapeutics is a biotechnology company developing gene therapy treatments for orphan diseases.

Biopharma · Paris$5.3M Grant
Positrigo
June 2025

Positrigo is a company dedicated to the development, production, and sales of dedicated brain positron emission tomography (PET) scanners.

Health Care · Zúrich$8.5M Venture - Series Unknown
Tribune Therapeutics
March 2025

Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

Biotechnology · Stockholm$24.8M Series A
HelloBetter
March 2025

Leading provider of digital therapeutics for mental health: 10 DTx, 6 PDTx with universal reimbursement for 73m+ people, 33 clinical studies

Health Care · Berlin$6.4M Venture - Series Unknown
Aro Biotherapeutics
November 2023

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

Biotechnology · Philadelphia$41.5M Series B
Rampart Bioscience
October 2023

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.

Biopharma · La Jolla$85.0M Series A
Elsa
November 2021

Elsa is a platform for patient-driven research for better drugs, health, and prevention.

Biotechnology · Stockholm$4.4M Seed
Ultragenyx Pharmaceutical
November 2025

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

Biotechnology · Novato$400.0M Post-IPO Debt
SynOx Therapeutics
October 2024

SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.

Biotechnology · Dublin$92.0M Series B
Kivu Bioscience
October 2024

Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.

Biotechnology · San Francisco$92.0M Series A
Hemab
October 2025

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

Biotechnology · Copenhagen$157.0M Series C
GetEquity
December 2023

Providing RWA tokenization to traditional asset management

Asset Management · Lagos$120K Pre-Seed
ReelFruit
September 2021

ReelFruit is a fruit agribusiness in Nigeria.

Food and Beverage · Yaba$3.0M Series A
Doctrin
June 2021

Doctrin provides decision support systems and communication tools to healthcare providers.

Health Care · Stockholm$15.7M Series C

Where HealthCap invests

Biotechnology17
Health Care15
Medical10
Therapeutics10
Pharmaceutical9
Life Science3

About HealthCap's portfolio

How many companies has HealthCap invested in?

HealthCap has invested in 37 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does HealthCap invest in?

HealthCap's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 25 different industry categories.

What is HealthCap's largest investment?

Among tracked funding rounds, Ultragenyx Pharmaceutical received $400.0M in a Post-IPO Debt round. HealthCap's total known invested capital is $1.6B.

What is the average investment size for HealthCap?

HealthCap's average investment size is $47.1M across its portfolio of 37 companies.

What are HealthCap's most recent investments?

Recent HealthCap portfolio additions include Carisma Therapeutics, CurifyLabs, Pretzel Therapeutics, Oncorena, Modus Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 37 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →